The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study.
Journal
Journal of public health research
ISSN: 2279-9028
Titre abrégé: J Public Health Res
Pays: United States
ID NLM: 101580775
Informations de publication
Date de publication:
05 May 2021
05 May 2021
Historique:
received:
10
03
2021
accepted:
14
04
2021
pubmed:
8
5
2021
medline:
8
5
2021
entrez:
7
5
2021
Statut:
epublish
Résumé
the aim was to verify the association between Major Depressive Disorders (MDD) and the risk of premature death in people with oncological diseases, and to collect evidence about the causality of a possible association from a longitudinal perspective. it is a cohort study lasting 9 months, involving people with solid or hematologic cancers. The assessment was conducted by an ad hoc form to collect socio-demographic and clinical-oncological data, the PHQ-9 to screen MDD (cut-off ≥10) and the SF-12 to evaluate HRQoL. Relative Risk (RR) of early death between MDD exposed and not-exposed and Kaplan-Meier survival were carried out. people exposed to MDD during the follow-up were 107/263 (40.7%). Among them, 36 deceased during the observation period. Overtime, having MDD and death' occurrence showed a strong association (RR=2.15; 95% CI (1.10-4.20); χ²=5.224, p=0.0022), confirmed by Kaplan-Meier survival analysis (χ²=4.357, p=0.037). Among people who died, there was not any association between MDD, age, gender, HRQoL, cancer stage and site. the study confirms the association between MDD and early death in people with cancer. The absence of any association between the onset of MDD and advanced stage of cancer may suggest that it could be due to the consequences of MDD in worsening the clinical conditions related to cancer. The findings point out the relevance of MDD' early detention among people with cancer.
Sections du résumé
BACKGROUND
BACKGROUND
the aim was to verify the association between Major Depressive Disorders (MDD) and the risk of premature death in people with oncological diseases, and to collect evidence about the causality of a possible association from a longitudinal perspective.
DESIGN AND METHODS
METHODS
it is a cohort study lasting 9 months, involving people with solid or hematologic cancers. The assessment was conducted by an ad hoc form to collect socio-demographic and clinical-oncological data, the PHQ-9 to screen MDD (cut-off ≥10) and the SF-12 to evaluate HRQoL. Relative Risk (RR) of early death between MDD exposed and not-exposed and Kaplan-Meier survival were carried out.
RESULTS
RESULTS
people exposed to MDD during the follow-up were 107/263 (40.7%). Among them, 36 deceased during the observation period. Overtime, having MDD and death' occurrence showed a strong association (RR=2.15; 95% CI (1.10-4.20); χ²=5.224, p=0.0022), confirmed by Kaplan-Meier survival analysis (χ²=4.357, p=0.037). Among people who died, there was not any association between MDD, age, gender, HRQoL, cancer stage and site.
CONCLUSIONS
CONCLUSIONS
the study confirms the association between MDD and early death in people with cancer. The absence of any association between the onset of MDD and advanced stage of cancer may suggest that it could be due to the consequences of MDD in worsening the clinical conditions related to cancer. The findings point out the relevance of MDD' early detention among people with cancer.
Identifiants
pubmed: 33960184
doi: 10.4081/jphr.2021.2247
pmc: PMC8506198
doi:
Types de publication
Journal Article
Langues
eng
Références
Death Stud. 2020 Dec 7;:1-10
pubmed: 33287686
Cochrane Database Syst Rev. 2012 Nov 14;11:CD007064
pubmed: 23152241
J Affect Disord. 2009 Feb;113(1-2):127-32
pubmed: 18558439
BMC Med. 2018 Jul 20;16(1):112
pubmed: 30025524
JCO Clin Cancer Inform. 2019 Sep;3:1-8
pubmed: 31545654
Patient Educ Couns. 2016 Jul;99(7):1099-1105
pubmed: 26879805
Nat Rev Cancer. 2008 Nov;8(11):887-99
pubmed: 18846100
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Clin Pract Epidemiol Ment Health. 2020 Jul 30;16:174-179
pubmed: 32874192
Am Psychol. 2015 Feb-Mar;70(2):186-97
pubmed: 25730724
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Lancet Psychiatry. 2017 Feb;4(2):146-158
pubmed: 27856392
Psychol Bull. 2011 Nov;137(6):959-97
pubmed: 21787044
Psychiatr Clin North Am. 2012 Mar;35(1):231-47
pubmed: 22370500
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
J Natl Cancer Inst. 2014 Sep 29;106(9):
pubmed: 25265940
Crit Rev Oncol Hematol. 2010 Aug;75(2):122-37
pubmed: 19604706
Cancer. 2011 Jan 1;117(1):218-27
pubmed: 20737537
Mol Psychiatry. 2013 May;18(5):595-606
pubmed: 22525486
Am J Psychiatry. 2014 Apr;171(4):453-62
pubmed: 24434956
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Cancer. 2009 Nov 15;115(22):5349-61
pubmed: 19753617
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
J Neuroinflammation. 2013 Apr 01;10:43
pubmed: 23547920
Cancer Treat Rev. 2017 Jan;52:58-70
pubmed: 27894012
JAMA. 1989 Sep 1;262(9):1191-5
pubmed: 2761060
Eur J Cancer. 2017 Feb;72:46-53
pubmed: 28024266
Support Care Cancer. 1996 Mar;4(2):129-40
pubmed: 8673350
Cancer. 2017 Nov 1;123(21):4236-4243
pubmed: 28654189
Lancet Oncol. 2004 Oct;5(10):617-25
pubmed: 15465465
J Oncol Pract. 2015 Mar;11(2):133-4
pubmed: 25515721
Psychooncology. 2014 Feb;23(2):121-30
pubmed: 24105788
Ann Surg Oncol. 2013 Jun;20(6):1941-8
pubmed: 23263699
Cochrane Database Syst Rev. 2018 Apr 23;4:CD011006
pubmed: 29683474
Clin Pract Epidemiol Ment Health. 2010 Aug 27;6:94-100
pubmed: 21253459
Psychol Med. 2000 Jul;30(4):831-40
pubmed: 11037091
Medicine (Baltimore). 2015 Nov;94(45):e0897-0
pubmed: 26559246